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OPEN
ORIGINAL ARTICLE
Modiﬁcations of the endosomal compartment in peripheral
blood mononuclear cells and ﬁbroblasts from Alzheimer’s
disease patients
F Corlier1,2,3, I Rivals4, J Lagarde5, L Hamelin5, H Corne5, L Dauphinot1,2,3, K Ando1,2,3, J-C Cossec1,2,3, G Fontaine1,2,3, G Dorothée6,7,
C Malaplate-Armand8,9, J-L Olivier8,9, B Dubois10, M Bottlaender11, C Duyckaerts1,2,3,12, M Sarazin5,13, M-C Potier1,2,3,13 and the Clinical
ImaBio3 team14
Identiﬁcation of blood-based biomarkers of Alzheimer’s disease (AD) remains a challenge. Neuropathological studies have
identiﬁed enlarged endosomes in post-mortem brains as the earliest cellular change associated to AD. Here the presence of
enlarged endosomes was investigated in peripheral blood mononuclear cells from 48 biologically deﬁned AD patients (25 with mild
cognitive impairment and 23 with dementia (AD-D)), and 23 age-matched healthy controls using immunocytochemistry and
confocal microscopy. The volume and number of endosomes were not signiﬁcantly different between AD and controls. However,
the percentage of cells containing enlarged endosomes was signiﬁcantly higher in the AD-D group as compared with controls.
Furthermore, endosomal volumes signiﬁcantly correlated to [C11]PiB cortical index measured by positron emission tomography in
the AD group, independently of the APOE genotype, but not to the levels of amyloid-beta, tau and phosphorylated tau measured in
the cerebrospinal ﬂuid. Importantly, we conﬁrmed the presence of enlarged endosomes in ﬁbroblasts from six unrelated AD-D
patients as compared with ﬁve cognitively normal controls. This study is the ﬁrst, to our knowledge, to report morphological
alterations of the endosomal compartment in peripheral cells from AD patients correlated to amyloid load that will now be
evaluated as a possible biomarker.
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INTRODUCTION
An estimated 35 million people worldwide suffer from dementia,
and this number, predicted to double every 20 years, will rise to
more than 65 million in 2030 and more than 115 million in 2050.1
Alzheimer’s disease (AD) is the most common cause of dementia.
New proposals for the diagnosis of AD combine clinical tools and
biological markers such as cerebrospinal ﬂuid (CSF) biomarkers
and amyloid positron emission tomography (PET) imaging for
identifying the underlying AD pathophysiological process. This
approach allows establishing a clinical diagnosis of AD at the stage
of mild cognitive impairment (MCI), before dementia, but needs
invasive and expansive tools.2
Autopsy still remains the only fully reliable diagnosis. AD
is neuropathologically characterized by extracellular amyloid
plaques composed of β-amyloid peptides (Aβ) and intracellular
neuroﬁbrillary tangles constituted of hyperphosphorylated tau
protein.3 Although the degree of tauopathy correlates strongly
with cognitive decline in AD, the aggregation of Aβ has a critical
role as early trigger, and recent longitudinal PET imaging studies
indicated that cerebral Aβ deposition precedes the clinical
symptoms of AD by a decade or more.4,5
One of the main challenges associated with the diagnosis of AD
is the identiﬁcation and validation of blood-based biomarkers.
Among different tracks, neuropathological and clinical data
suggested the presence of enlarged endosomes as a candidate
cellular biomarker in the blood.
Indeed dysregulation of the endolysosomal compartment has
been found in the brain of AD patients.6,7 Neurons bearing
enlarged endosomes were identiﬁed as the earliest morphological
change observed in post-mortem brains from patients with
sporadic AD before the onset of clinical symptoms.8,9 Although
familial AD cases with mutations in the amyloid precursor protein
gene harboured the same endosomal phenotype, cases with
mutations in the presenilin genes did not.10 Enlarged endosomes
were also observed in individuals with Down syndrome (DS) who
are at high risk for AD (45% of DS people have AD at 60 years
1UPMC University Paris 06, UMRS 1127, Sorbonne Universités, Paris, France; 2INSERM U 1127, Paris, France; 3ICM Research Centre, CNRS UMR 7225, Paris, France; 4Équipe de
Statistique Appliquée, ESPCI ParisTech, PSL Research University, INSERM UMRS 1158, Paris, France; 5Neurologie de la Mémoire et du Langage, Service de Neurologie, Université
Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France; 6INSERM UMRS 938, Laboratoire Système Immunitaire et Maladies
Conformationnelles, Hôpital Saint-Antoine, Paris, France; 7Université Pierre et Marie Curie, Université Paris 6, Centre de Recherche Saint-Antoine, Hôpital Saint-Antoine, Paris,
France; 8Laboratoire de Biochimie et Biologie Moléculaire, UF Oncologie—Endocrinologie—Neurobiologie, Hôpital Central, Centre Hospitalier Universitaire, Nancy, France; 9UR
AFPA—USC 340, Equipe BFLA, Université de Lorraine, Nancy, France; 10Institut de la mémoire et de la maladie d’Alzheimer, IMMA, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris,
France; 11CEA (MB), DSV, Institut d’Imagerie Biomédicale, Service Hospitalier Frédéric Joliot, Orsay, France and 12Laboratoire de Neuropathologie Escourolle, Hôpital de la Pitié-
Salpêtrière, AP-HP, Paris, France. Correspondence: Dr M-C Potier, ICM Research Centre, Group of Alzheimer's and Prion's diseases, CNRS UMR7225, INSERM URM975, UPMC,
Hôpital de la Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, 75013 Paris, France.
E-mail: marie-claude.potier@upmc.fr
13These two authors contributed equally to this work.
14Members of the Clinical ImaBio3 team are listed before References.
Received 23 February 2015; accepted 21 May 2015
Citation: Transl Psychiatry (2015) 5, e595; doi:10.1038/tp.2015.87
www.nature.com/tp
against ~ 3% in the general population).11 In DS, enlarged
endosomes have been identiﬁed not only in neuronal cells but
also in peripheral cells such as peripheral blood mononuclear cells
(PBMCs), lymphoblastoids and ﬁbroblasts.12,13
AD genome-wide association studies suggest a crucial role of
several proteins involved in membrane trafﬁcking such as PICALM,
SORL1, BIN1.14 In addition, several endolysosomal proteins such as
EEA1, Rab3, Rab7, LAMP1 and LAMP2 were found increased in the
CSF of AD patients.15 These data suggest that endosomal
dysmorphologies could be associated with amyloid pathology in
AD and could thus be detected in blood cells from AD patients at
an early stage of the disease.
In this study, we applied the immunocytochemical method that
we developed earlier for analysing the endosomal compartment
of PBMCs from DS patients13 to isolated PBMCs from 48
biologically conﬁrmed AD patients (25 with mild cognitive
impairment (AD-MCI) and 23 at the dementia stage (AD-D)) and
23 cognitively normal controls, with no evidence of preclinical AD
(negative for the amyloid imaging). Results were conﬁrmed in
ﬁbroblasts from six independent AD-D patients and ﬁve cogni-
tively normal controls. We hypothesised that the endosomes in




PBMCs were analysed from 71 subjects, enrolled in the ImaBio3 study (NCT:
NCT01775696). Forty-eight AD patients with biologically conﬁrmed AD
were included according to the following criteria: (1) predominant and
progressive episodic memory impairment, characterized by low free recall
not normalized with cueing (free recall 419/48 and total recall o41/48
in the Free and Cued Selective Reminding Test, FCSRT), associated or not
with other cognitive impairments; (2) biological evidence of AD
pathophysiological process as deﬁned by CSF AD biomarker proﬁle
and/or signiﬁcant amyloid retention on PET with [C11]- labelled Pittsburgh
Compound B ([C11]PiB). A CSF AD biomarker proﬁle was deﬁned as score
o0.8 for the ratio of Aβ 42/tau, calculated with the formula Aβ 42/[240
+(1.18 × total tau)].16 Signiﬁcant ﬁxation of [C11]PiB on PET was deﬁned by
a global cortical index higher than 1.4.17 We excluded subjects who had
clinical or neuroimaging evidence of focal lesions, severe cortical or
subcortical vascular lesions on magnetic resonance imaging and severe
depression.
Patients were stratiﬁed according to disease severity assessed by the
Clinical Dementia Rating scale (CDR): 25 patients had a score of 0.5
representing AD-MCI with isolated episodic memory impairments and only
moderated impact on the activities of daily living, and 23 patients had a
CDR scale score 40.5 representing AD-D.
Twenty-three healthy elderly control subjects were selected according
to the following criteria: (1) MMSE (Mini Mental State Examination) ⩾ 27
and normal neuropsychological testing; (2) no history of psychiatric or
neurologic conditions, (3) no evidence of focal lesion or severe cortical or
subcortical vascular lesions on magnetic resonance imaging.
To improve diagnostic accuracy, all the subjects had at least one 12-
month follow-up to validate the AD diagnosis according to their clinical
evolution, or the absence of cognitive decline for controls.
The study was conducted by the Assistance Publique des Hôpitaux de
Paris (PHRC-0053-N) and was approved by the Ethics Committee of Pitié-
Salpêtrière Hospital. All the subjects provided written, informed consent
before participating.
Analysis of ﬁbroblasts
Fibroblasts were obtained independently from a regional PHRC (Projet
Hospitalier de Recherche Clinique) in 2003 coordinated by the Centre
Hospitalo-Universitaire of Nancy (France). Eleven additional participants
without a known family history of AD were enrolled: six patients with
sporadic AD-D (mean age: 78.5 ± 7.77, MMSE o25) and ﬁve healthy
volunteers (mean age: 70.8 ± 8.01, MMSE= 30). Skin biopsies taken from
the upper arm were explanted and grown in DMEM-glutamax supple-
mented with 10% fetal bovine serum, 100 units ml− 1 penicillin and 100 -
μgml− 1 streptomycin (Gibco BRL, Life Technologies, Saint Aubin, France,
European Division) at 37 °C in humidiﬁed air with 5% CO2. Experiments on
AD and control ﬁbroblasts were performed at the same stage of doubling
in culture (o12 passages).
Participants were selected in accordance with local ethic recommenda-
tions: CCPPRB (Comité Consultatif de Protection des Personnes dans la
Recherche Biomédicale) de Lorraine n° 04-03-01.
For both groups, all the subjects provided written informed consent
before participating.
Biological markers
CSF biomarker analysis. For the Imabio3 study, CSF samples obtained by
lumbar puncture were processed with the same procedures described
previously18 to obtain CSF levels of total tau, phosphorylated tau at
threonine 181 (P-Tau) and amyloid-β peptide 1–42 (amyloid-β42) by using
enzyme-linked immunosorbent assay kits (Innogenetics), according to the
manufacturer's instructions. All the operators were masked to clinical
information. CSF biomarkers were available for 36/48 AD patients, among
whom 20/25 were AD-MCI. Controls did not have lumbar punction for
ethical reasons.
[C11]PiB PET imaging procedures. For the Imabio3 study, PET imaging with
[C11]PiB was performed in 19 control subjects and in 43/48 AD patients,
among whom 23/25 were AD-MCI. The method was the same as previously
described.17 In summary, a global cortical index was deﬁned by the mean
standard uptake value ratio (with the cerebellum as the reference region)
of the following cortical regions: (1) frontal cortex, by grouping the orbito-
frontal, polar prefrontal and dorsolateral cortex; (2) anterior cingulate;
(3) medial cingulate; (4) posterior cingulate; (5) precuneus; (6) occipital
cortex, by grouping the calcarine cortex, occipital cortex and cuneus;
(7) temporal cortex, by grouping the anterior and lateral temporal cortex;
(8) hippocampus; and (9) parietal cortex, by grouping the inferior and
superior parietal cortex and the parietotemporal junction.
Measures of enlarged endosomes
PBMC isolation from blood samples: For each participant, 10 ml
blood was collected in heparin-coated tubes (Vacutainer, Beckton-
Dickinson, Franklin Lakes, NJ, USA). Blood samples were diluted in one
volume of phosphate-buffered saline and PBMCs isolated by centrifugation
on a 1077 gml− 1 ﬁcoll gradient (15 ml preﬁlled ﬁltered Leucosep PANCOLL
tubes, PAN Biotech, Aidenbach, Germany) following the manufacturer’s
instructions. After centrifugation, PBMCs were re-suspended in 200 μl of
reduced serum culture medium (Gibco OPTI-MEM) and incubated at 37 °C,
5% CO2 for 1 h, then rinsed and ﬁxed for 12min in 4% cold
paraformaldehyde and rinsed in 10ml phosphate-buffered saline.
Culture of ﬁbroblast: Fibroblasts were grown directly on microscope
coverslips in 24-well plates, in DMEM supplemented with 10% FCS and
100 μgml− 1 penicillin+streptomycin, for 24 to 48 h. Cells were ﬁxed before
reaching conﬂuence in 4% cold paraformaldehyde for 15min and rinsed
three times with phosphate-buffered saline. The number of passages was
between 3 and 12 at the time of analysis.
Immunocytochemistry: Paraformaldehyde-ﬁxed PBMCs were incu-
bated with 2% normal goat serum for 20min and permeabilized 20min
in Triton 0.1% X-100. For staining of EEA1, cells were re-suspended in 1:100
solution of Polyclonal antibody (Cell signalling, Rabbit-anti-Human #2411)
in 2% normal goat serum at 5 °C overnight. Cells were rinsed in phos-
phate-buffered saline twice and incubated with 1:500 Alexa-488®-
conjugated Goat-anti-Rabbit antibody (A-11034, Invitrogen) in 2% normal
goat serum, for 2 h at room temperature. Slides were mounted by
mixing 10 μl of re-suspended cells in 10 μl mounting medium (South-
ernBiotech, ﬂuoromount-G) and sealed after one night air drying at room
temperature.
For ﬁbroblasts, EEA1 immuno-staining was performed following the
same protocol directly on coverslips with an additional staining of nuclei
before the last wash using DAPI for 2.5 min. Mounting was performed by
applying coverslips upside down on a drop of mounting medium and
sealed after one night air drying at room temperature.
Confocal imaging: Immunoﬂuorescent labelling was observed under
an upright confocal microscope (Olympus Fluoview Fv1000) using a × 63
(NA 1.40) apochromatic objective. All PBMC images were performed at the
same magniﬁcation. (Voxel size for PBMC: XY= 0.073 μm, Z= 0.25 μm). Due
to the large size of ﬁbroblasts, we applied a lower magniﬁcation (Voxel
size: XY= 0.094 μm, Z=0.25 μm). Approximately 20 cells per subject for
PBMCs and 15 cells per subject for ﬁbroblasts were chosen randomly on
the slides and scanned individually by deﬁning the upper and lower
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position of the scanning device and by ﬁxing the space between slides to
250 nm (the actual depth of ﬁeld of the objective) to sample the whole cell
volume for subsequent three-dimensional image treatment.
Image analysis of the endosomes: The three-dimensional recon-
structed images were analysed applying a wavelet-based detection
method19 implemented as a plugin spot detector in Icy software20
(http://icy.bioimageanalysis.org.) as described earlier for the analysis of
cells from DS individuals.13 The size was expressed as the number of voxels
in the detection, and when needed, converted in cubic micrometres (μm3)
according to voxel size. Staining and image analysis were performed
blindly by the same operator to guarantee anonymous and unbiased
interventions at all levels of sample processing and to avoid inter-operator
variability.
Automated data processing: Data extraction and analysis was
automatized using MATLAB version 8.3.0.73043 (R2014a). The function
selects relevant data in the single result ﬁles provided by Icy software for
each cell, and implements a concatenated database of all subjects by
classifying them automatically with respect to clinical information, relating
every single detected endosome to the cell, as well as to the individual and
his clinical information.
Statistical analysis
The statistical analysis was performed with MATLAB’s Statistics Toolbox
Version 9.0 (R2014a).
Comparison of the endosome number and mean volume per cell. The
endosome numbers and mean volumes per cell of the three groups, that
is, the control group (23 patients, 459 cells), the MCI-AD group (25 patients,
497 cells) and the AD group (23 patients, 455 cells) were compared with an
analysis of variance with a ﬁxed group effect and a random individual
effect. To normalize the distributions and to homogenize their variances,
the analysis of variance was performed on the logarithm of the mean
numbers and volumes.
Comparison of the mean endosome volume distribution between groups.
To compare the distributions of the endosome volumes per cell in the
three groups, we classiﬁed the mean volumes in size categories. The
distributions being heavily skewed to the right (overall skewness and
kurtosis of 2.7 and 16.6, respectively), we chose the median and ninth
decile of the control group volumes as the limits of three size categories
small, medium and large. The distributions of the mean endosome
volumes per cell in the three size categories of the three groups were then
compared with a χ2 test. Further χ2 tests were used to perform the three
two-by-two comparisons between groups, that is, controls/AD, controls/
MCI-AD and MCI-AD/AD; the P-values of the latter were adjusted for
multiple testing using the Bonferroni correction.
As the analysis of variance had shown a signiﬁcant individual effect on
the mean endosome volume per cell, we used bootstrap sampling at the
individual level (1000 samples were randomly drawn) to assess the stability
of the distributions across the size categories and of the signiﬁcance of the
difference between the distributions in the control and AD groups.
Correlation of the mean endosome volume with the clinical data. Pearson’s
correlation was computed between the mean endosome volume of the
patients (MCI-AD and AD) and their amyloid load measured by PiB




Morphometric analyses of early endosomes (number and volume)
in PBMCs were obtained from 48 patients with AD (23 AD and 25
MCI-AD) and 23 healthy controls at inclusion (Table 1).
There were no signiﬁcant differences in sex and age across the
AD-MCI, AD-D and control groups. As expected, there were
signiﬁcant differences across the diagnostic groups (MCI-AD and
AD) for APOE ε4 status, amyloid burden and cognitive deﬁcits
(MMSE and CDR) with AD and MCI-AD groups having more APOE
ε4 carriers and poorer performance on cognitive assessments as
compared with healthy controls. Individual data are presented as
Supplementary Material (Supplementary Table).
Table 1. Demographic and clinical data of analysed groups
Controls AD-MCI AD-D
PBMC analysis
Number of individuals (N) 23 25 23
Sex ratio (F/M) 13/10 14/11 12/11
Age 67± 10.39 (51–86) 67.68± 9.7 (52–82) 69.43 ± 11.6 (51–91)
MMSE 29.9± 0.92 (27–30) 23.7± 3.19 (18–30) 15.43± 4.9 (4–22)
CDR= 0.5 — 25 —
CDR= 1 — — 23
APOE ε4/ - 2/23 10/25 7/23
ε4/ε4 0/23 7/25 5/23
[11]C-PIB PET scan 20/23 23/25 20/23
Lumbar puncture — 20/25 16/23
Number of analysed cells 454 460 427
% Cells with small MEV 50.1 51.7 46.8
% Cells with medium MEV 39.9 34.8 35.8
% Cells with large MEV 10.0 13.5 17.4
Fibroblast analysis
Number of individuals (N) 5 — 6
Sex ratio (F/M) 5/0 — 1/5
Age 70.8± 8.01 (63–83) — 78.5± 7.77 (69–88)
MMSE 30 18± 2.45 (16–21)
APOE ε4/ - 0/5 — 2/6
ε4/ε4 1/5 — 1/6
Number of analysed cells 76 90
% Cells with small MEV 50.0 31.1
% Cells with medium MEV 39.5 42.2
% Cells with large MEV 10.5 26.7
Abbreviations: AD-D, Alzheimer’s disease with dementia; AD-MCI, Alzheimer’s disease with mild congnitive impairment; CDR, Clinical Dementia Rating; MEV,
mean endosome volume; MMSE, Mini Mental State Examination; PBMC, peripheral blood mononuclear cell; PET, positron emission tomography.
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Analysis of the mean endosome volume and number in PBMCs
The PBMCs from all patients with AD-D, AD-MCI and healthy
controls were puriﬁed from fresh blood, ﬁxed and their early
endosomes stained by immunocytochemistry using an antibody
against early endosome antigen 1 (EEA1). Z-stack images of ~ 20
cells for each individual were obtained under the confocal
microscope.
Figures 1a–c show representative images obtained from PBMCs
of control, AD-MCI and AD-D individuals. Videos of three-
dimensional reconstructed images are available as
Supplementary Material (Supplementary Videos 1–3).
Endosomes present in the whole cell volume were detected
with the spot detector plugin of Icy software.20 Volumes of
individual endosomes were measured as voxels. A total of 459,
497 and 455 cells were analysed in the healthy control, AD-MCI
and AD-D groups, respectively. For each individual, mean
endosome number (MEN) and mean endosome volume (MEV)
per cell were calculated. Figures 1d and e show boxplots of
individual values for the healthy controls, AD-MCI and AD-D cases.
Individual data are presented as Supplementary Material
(Supplementary Table).
According to analysis of variance, MEN and MEV were not
signiﬁcantly different either between AD-MCI, AD-D and control
groups (Pgroup = 0.63 for MEN and 0.61 for MEV) or between AD
group (AD-MCI and AD-D) and controls. The MENs per cell
were 22.47 for the controls, 20.12 for the AD-MCI and 21.92 for the
AD-D. The MEVs per cell were 214.90, 214.81 and 233.83 voxels
corresponding to 0.286 and 0.311 μm3 in the control/AD-MCI and
AD-D groups, respectively.
To verify between-day variability of endosome size and number
measurements for a given subject, we analysed blood samples
drawn from the same individual with no cognitive decline at 1-
month interval. No signiﬁcant difference was found in MEV and
MEN (Student’s t-test, P= 0.29 and 0.17, respectively, data not
shown).
Analysis of the endosome size distribution
We then categorized the 459, 497 and 455 cells from the healthy
control, AD-MCI and AD-D groups, respectively, in three classes
according to their mean endosomal volume. Small, medium and
large were deﬁned as classes containing endosomes with mean
volume below the median (o0.256 μm3; small), between the
ninth decile and the median (0.256 to 0.412 μm3; medium) and
above the ninth decile (40.412 μm3; large) in the control group.
Figure 2a shows the percentage of cells with MEV of the three
classes for the three groups. A higher percentage of cells with
larger MEV were found in the AD groups (13.5 and 17.4% for the
AD-MCI and the AD-D, respectively) as compared controls (10.0%).
Endosome size distributions were signiﬁcantly different for the
AD-D and the control groups (Bonferroni corrected P= 6.4 10− 3 of
χ2 test).
Figure 1. Endosomal abnormalities are present in peripheral mononuclear blood cells (PBMCs) from individuals with AD-MCI and AD-D. (a–c)
Immunoﬂuorescence confocal images showing EEA1-labelled early endosomes in representative PBMCs from cognitively healthy subjects (a),
AD-MCI (b) and AD-D cases (c). Scale bar, 2 μm. Mean endosome volumes (MEVs) (d) and mean endosome numbers (MENs) (e) per PBMC are
not signiﬁcantly different between AD-D (455 cells), AD-MCI (497 cells) and controls (CT, 459 cells). Pgroup= 0.63 for MEN and 0.61 for MEV
according to analysis of variance. AD-D, Alzheimer’s disease with dementia; AD-MCI, Alzheimer’s disease with mild congnitive impairment.
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We conﬁrmed the stability of these size distributions by drawing
1000 bootstrap samples at the individual level: the percentage of
cells with large MEV was signiﬁcantly higher in the AD groups as
compared with control individuals (Bonferroni corrected Po0.05)
in 98% of the bootstrap samples. Means and standard deviations
on the bootstrap samples are shown in Figure 2b. These data
suggest that the size distribution of endosome was distinct
between healthy controls and AD groups.
Analysis of samples from the same control individual drawn at
1-month interval did not show any difference in the distribution of
mean endosomal volume (P= 0.12 of χ2 test, data not shown).
Correlation between the mean endosomal volume per cell and the
cortical amyloid burden assessed by [C11]PiB PET
We then wondered what could cause the increase in the
percentage of cells with bigger endosomes in the AD-MCI and
AD-D cases. Since Aβ levels and APOE ε4 status have been shown
to be associated with the increase in the size of early endosomes
observed in neurons from AD patients,9 we analysed the potential
correlation between amyloid burden, the APOE status and the
mean endosomal volumes in the AD groups.
Pearson’s correlations were used to test the level of overlap
between endosomal volume and global amyloid burden mea-
sured by [C11]PiB retention. We found a signiﬁcant positive
correlation between MEV and global amyloid burden in 43 AD-MCI
and AD-D patients (r= 0.415, P= 0.008 after adjustment for age
and APOE ε4; Figure 3). High correlation was found in the
precuneus, a region with greatest levels of amyloid load21
(r= 0.402, P= 0.018 after adjustment for age and APOE ε4).
In addition, we found a positive correlation (0.88) between MEV
and the APOE ε4 status (0, 1 or 2 alleles), although this correlation
was below statistical signiﬁcance (0.16, data not shown). MEV was
also more strongly correlated to PiB retention (r= 0.682, P= 0.0001
as compared with r= 0.415, P= 0.008, see above) when we
analysed AD-MCI and AD-D APOE ε4 carriers only (28 individuals,
Figure 3, dots in red).
Finally, we did not ﬁnd any correlation between the MEV and
other parameters such as the levels of Aβ, tau or P-tau in the CSF,
age and sex (data not shown).
Analysis of the endosomal compartment in ﬁbroblasts from AD-D
individuals
To conﬁrm the presence of abnormally larger endosomes in
peripheral cells from AD patients, we analysed the endosomal
compartment of ﬁbroblasts isolated from six independent AD-D
patients (90 cells) and ﬁve age-matched controls (76 cells).
Figures 4a and b show representative images obtained from
ﬁbroblasts of control (a) and AD-D individuals (b). Instead of
reporting the number of endosomes per cell, which would be
biased by the particularly high variability of shape and size among
ﬁbroblasts, we compared the density of endosomes per cell, the
Figure 2. Percentage of PBMCs containing enlarged endosomes is signiﬁcantly higher in AD-D as compared with control (CT) individuals. (a)
Classiﬁcation of cells in three subclasses according to their MEV (small/medium/large) and (b) mean percentages and standard deviations on
1000 bootstrap samples drawn at the individual level. AD-D, Alzheimer’s disease with dementia; AD-MCI, Alzheimer’s disease with mild
congnitive impairment; MEV, mean endosome volume; PBMC, peripheral blood mononuclear cell.
Figure 3. Correlation between mean endosomal volume in AD
patients (AD-MCI and AD-D) and their PiB retention. Black dots
correspond to non-APOE ε4 carriers and red dots to APOE ε4 carriers;
r= 0.682, P= 0.0001 and r= 0.415, P= 0.008 for all AD patients (black
and red dots) and APOE ε4 carriers only (red dots) after adjusting for
age and APOE ε4. AD-D, Alzheimer’s disease with dementia; AD-MCI,
Alzheimer’s disease with mild congnitive impairment; PiB, Pittsburgh
Compound B.
Enlarged endosomes in blood cells in Alzheimer’s disease
F Corlier et al
5
Translational Psychiatry (2015), 1 – 8
number of endosomes per cell divided by its volume obtained by
calculating the convex hull of all endosomes. As for PBMCs,
neither the mean density nor the MEV was signiﬁcantly different
between AD-D and controls (Figures 4c and d).
We then categorized the 76 and 90 cells from the healthy
control and AD-D groups, respectively, in three classes according
to their mean endosomal volume. Small, medium and large were
deﬁned as classes containing endosomes with mean volume
below the median (o0.14 μm3; small), between the ninth decile
and the median (0.141 to 0.19 μm3; medium) and above the ninth
decile (40.191 μm3; large) in the control group. Figure 5 shows
the percentage of cells with MEV of the three classes: 50% small,
39.5% medium and 10.5% large for the controls and 31.1% small,
42.2%medium and 26.7% large for the AD-D. A signiﬁcantly higher
percentage of cells with larger MEV was found in the AD-D group
as compared with controls (χ2 test, P= 0.0094).
DISCUSSION
Previous studies which aimed at identifying blood biomarkers in
AD were based on large longitudinal cohorts using top down
approach.22 Here, we used a hypothesis-driven approach based on
a very well-deﬁned population of AD patients. We applied strict
inclusion criteria based on both positive clinical/cognitive and
pathophysiological markers (CSF biomarkers and [C11]PiB PET).
More importantly, all healthy controls had negative cortical [C11]
PiB retention, thus excluding presymptomatic AD. We focused our
research on the analysis of the endosomal compartment, a
putative cellular biomarker expected to be less sensitive to serum
components.
Across the three very well-deﬁned groups (AD-MCI, AD-D and
controls), we found a signiﬁcant increase in the percentage of cells
containing enlarged endosomes in AD patients as compared with
controls, even at an early stage of the disease (AD-MCI).
Figure 4. Endosomal abnormalities are present in ﬁbroblasts from individuals with AD-D. Immunoﬂuorescence confocal images showing
EEA1-labelled early endosomes (green) in representative ﬁbroblasts from cognitively healthy subjects (a) and AD-D cases (b). Nuclei are
labelled in blue. Scale bar, 2 μm. (c) Mean endosome volumes per ﬁbroblast are not signiﬁcantly different between control (CT) individuals
(0.147± 0.016 μm3) and AD-D patients (0.170± 0.034 μm3; Wilcoxon P= 0.18). (d) Comparison of the mean endosomal densities per ﬁbroblast
(that is, portion of the cell volume occupied by endosomes) showed no signiﬁcant difference between control individuals (0.0249± 0.005) and
AD-D patients (0.0279± 0.006; Wilcoxon P= 0.46). AD-D, Alzheimer’s disease with dementia; EEA1, early endosome antigen 1.
Figure 5. Percentage of ﬁbroblasts containing enlarged endosomes
is signiﬁcantly higher in AD-D as compared with control (CT)
individuals. Classiﬁcation of cells in three subclasses according to
their MEV (small/medium/large) showed signiﬁcantly elevated
percentage of cells with large MEV in AD-D patients and reduced
percentage of cells with small MEV (χ2 test, P= 0.0094). AD-D,
Alzheimer’s disease with dementia; MEV, mean endosome volume.
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Importantly, we conﬁrmed the presence of enlarged endo-
somes in ﬁbroblasts from another small cohort of AD-D patients
thus demonstrating the presence of endosomal abnormalities in a
second peripheral cell type.
These results support the recent line of evidence showing an
over-representation of genes involved in endocytosis as AD
genetic risk factors.23 It will be interesting in a next study to
include these genetic risk factors.
Enlarged endosomes have been previously identiﬁed in
neuronal cells of AD-D, AD-MCI and DS patients as well as in
peripheral cells from individuals with DS.9,12 Changes of the
endosomal compartment observed here in PBMCs were signiﬁ-
cantly correlated in the AD diagnostic groups with amyloid
burden assessed by PET using [C11]PiB retention. Notably, this
correlation was still valid after conditioning with age and APOE ε4
status. It thus appears that factors other than APOE ε4 allele and
age likely contribute to the change observed in the morphology of
early endosomes. Even though changes in the endosomal
compartment of neuronal cells appear speciﬁc of AD and DS,9 it
will be important to analyse the endosomal compartment of
peripheral cells in other types of neurodegenerative diseases than
AD or DS (present study and Cossec et al.13). At least no correlation
was found between MEV of PBMCs from AD patients and their age
suggesting that such changes in the endosomal compartment are
not correlated to age.
Aβ has been linked to endosomal dysfunctions in AD and DS.
Indeed enlarged endosomes in post-mortem brains of sporadic
AD and DS patients contain Aβ.9 However, enlarged endosomes
are present in DS brains before Aβ can be detected and conversely
enlarged endosomes are absent in familial AD brains with
mutations in presenilin1 overproducing Aβ.9 In DS ﬁbroblasts,
amyloid precursor protein C-terminal fragment (β-CTF) rather than
Aβ appeared to be related to endosomal dysfunction.24 It will be
interesting to compare the levels of β-CTF in ﬁbroblasts from
controls individuals and AD patients.
In PBMC from AD patients (MCI and D), we found that enlarged
endosomes are more strongly correlated to amyloid burden when
we stratiﬁed APOE ε4 carriers (Supplementary Figure 1). But since
this correlation in AD-D and AD-MCI was still valid after
conditioning with APOE genotype, the APOE genotype could
participate nonexclusively in the formation of enlarged endo-
somes in peripheral cells.
The levels of plasma APOE may be important for the
endososomal function as APOE ε4 carriers have lower levels of
plasma APOE4 protein that could predispose them to AD.25
However, APOE genotype does not inﬂuence the metabolism of
plasma Aβ peptides in young persons without memory deﬁcits.26
In addition, APOE ε4- but not ε4+ AD participants showed positive
relationships between plasma Aβ1–40/Aβ1–42 and PiB uptake.27
Macrophages are able to cross the blood–brain barrier and
phagocytize cerebral Aβ while Aβ-engorged macrophages are
adherent and cannot cross the blood–brain barrier back into the
blood.28 We were unable to detect Aβ in PBMCs using
immunocytochemistry (data not shown). Thus, the role of
peripheral Aβ in enlarged endosomes found in PBMC remains
unclear.
PBMCs are blood cells with a round nucleus including 70–90%
lymphocytes (T cells, B cells and NK cells), 10–30% monocytes and
few percentage of macrophages and dendritic cells. The higher
percentage of PBMCs containing enlarged endosomes observed
in AD and AD-MCI compared with healthy controls could be the
result of either a change of the endosomal compartment in a
subpopulation of cells or a change in a small percentage of all cell
types. Additional experiments of co-labelling of large endosome
bearing cells with selective markers, or cell sorting using a panel of
antibodies including anti-EEA1 will be necessary to conﬁrm one of
these hypotheses. However, as ﬁbroblasts also carry this enlarged-
endosome phenotype, we believe that endosomal changes are
more likely to be present in a small percentage of all cell types of
PBMCs rather than in a speciﬁc subpopulation.
Inﬂammation could also be involved in endocytosis and the
morphological changes of endosomes. As inﬂammation is a
hallmark of AD and the neutrophil–lymphocyte ratio was shown
to be elevated in AD, it will be interesting to test the correlation
between endosomal volume and the neutrophil–lymphocyte
ratio.29
We showed previously that higher cholesterol levels at the
plasma membrane of cultured cells and neurons induced
enlargement of early endosomes and subsequent increase of
Aβ.30–32 It is also well admitted that cholesterol levels are
increased in AD brains notably in membranes as well as in amyloid
plaques.33–35 As neutral lipids have been found to be increased in
a very high percentage of PBMCs in AD (85% compared with 7% in
controls), and cholesterol-related genes are also differentially
expressed in PBMC, it remains possible that cholesterol home-
ostasis could be involved in endosome changes observed in
PBMCs in AD patients.36,37
Nevertheless, it will be interesting to know whether some of the
endolysosomal proteins that have been shown to be increased in
the CSF of AD patients, including EEA1, are also changed in PBMC
or plasma.15
In conclusion, in this study, we found morphological alterations
of the endosomal compartment in blood cells (PBMCs) from
sporadic biologically conﬁrmed AD patients as well as in
ﬁbroblasts of clinically deﬁned independent sporadic AD patients
that may reﬂect amyloid pathology in the brain and could thus be
a new peripheral and blood biomarker. Future studies will
determine whether changes in the endosomal compartment in
PBMCs and ﬁbroblasts from the same patients are equally
correlated to amyloid load, how they evolve during the time
course of the disease and whether endosomal biomarkers, either
cellular or plasmatic, can be identiﬁed.
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